Search the Newsreel

Argenx enters biotech buyer class with $2.2B Forte takeout

Argenx has acquired Forte Biosciences for $2.2 billion, marking its entry into the large-cap biotech buyer class. This acquisition is funded entirely from Argenx's cash reserves, leveraging the financial success of its drug Vyvgart. The deal adds FB102, an anti-CD122 mAb, to Argenx's pipeline, …

Regenxbio Inc (RGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Regenxbio Inc's (RGNX) dividend and stock split history, indicating that no dividends have been distributed over the past five years. It presents current stock performance data, including its market cap and recent price change. The page is part …

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Beauty pharmaceutical research by Chokniti-Studio via Shutterstock Forte Biosciences (FBRX) ripped higher on Monday after the Dutch immunology giant, Argenx (ARGX), announced a definitive agreement to acquire it for $2.2 billion. The all-cash transaction is expected to close in the third quarter of 2026 …

argenx (Nasdaq: ARGX) to acquire Forte Biosciences in $2.2B cash tender offer

argenx SE has agreed to acquire Forte Biosciences, Inc. for approximately $2.2 billion through a cash tender offer of $77 per share. This acquisition, expected to close in Q3 2026, will add Forte's lead anti-CD122 antibody FB102, which has shown positive Phase 1b data …

Inventory turnover of REGENXBIO, Inc. – HAM:RB0

This article focuses on the inventory turnover of REGENXBIO, Inc. (HAM:RB0). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred. The content suggests the financial data provided is made by humans and …

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Argenx will acquire Forte Biosciences, the developer of an autoimmune disease drug that's shown early promise, in a deal worth up to …

Forte Biosciences Agrees to Be Acquired by Argenx in $2.2 Billion Deal

Forte Biosciences (FBRX) shares surged early Monday after the company agreed to be acquired by Belgi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx

Stock chart with green arrow moving up ©Adobe Stock Images Forte Biosciences (NASDAQ:FBRX) shares climbed 39.2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.2 billion. Under the terms …

Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline

Medical researcher in gloves using a tablet ©Adobe Stock Images Argenx NV ADR (NASDAQ:ARGX) has agreed to acquire Forte Biosciences Inc (NASDAQ:FBRX) in a transaction valued at approximately $2.2 billion, expanding its portfolio of autoimmune disease treatments as it looks to build new growth …

argenx strikes $2.2B deal for Forte Biosciences

[Colorful collage. Hands holding orange and blue puzzle pieces representing corporate merger and innovation] * argenx SE (ARGX [https://seekingalpha.com/symbol/ARGX]) to acquire [https://seekingalpha.com/pr/20595280-argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibody-fb102-to] Forte Biosciences (FBRX [https://seekingalpha.com/symbol/FBRX]) for $77 per share in cash, valuing the transaction at ~$2.2B. * The acquisition will add Forte’s lead …

argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX)

Argenx To Acquire Forte For Approx. $2.2 Bln To Expand Immunology Pipeline; Forte Shares Soar

(RTTNews) - Argenx (ARGX), an immunology company, and Forte Biosciences, Inc. (FBRX),a clinical-stage biopharmaceutical company on Monday announced that they have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value …

argenx Acquires Forte Biosciences for $2.2 Billion

argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion, paying $77 per share in cash. This acquisition is driven by Forte's FB102, which has shown positive Phase 1b results in vitiligo and celiac disease, thereby strengthening argenx's immunology portfolio and aligning with …

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high …

Argenx stock trades steady as efgartigimod growth offsets higher R&D spending

Argenx's stock reflects a balance between the rapid revenue growth of its antibody fragment therapy, efgartigimod, and significant R&D investments. Recent quarterly reports show total revenue reached $388 million, driven by efgartigimod's launch, while R&D spending increased to $210 million. Despite increased costs, the …

Regenxbio Inc (RGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Regenxbio Inc (RGNX), detailing its price momentum score, current trading range, and a summary of technical indicators and moving averages. RGNX currently has a price momentum score of 5.89 and is trading between a resistance level of …

Argenx stock holds as investors await the next update

Argenx (NL0010832176), a Netherlands-based biotech group, continues to be a closely watched stock, with its performance primarily driven by quarterly execution, pipeline milestones, and share-price positioning. Investors are focused on the company's antibody platform, rare-disease franchise, and the impact of treatment adoption and pipeline …

Argenx stock trades steady as Uplizna growth and Vyvgart expansion shape outlook

Argenx stock reflects a company transitioning from a development stage to a commercial autoimmune specialist, driven by robust double-digit revenue growth from Vyvgart and Uplizna, alongside substantial ongoing investments in R&D. The company's recent quarterly results highlight expanding patient access and successful commercialization of …

REGENXBIO Inc. Revenue Breakdown – NASDAQ:RGNX

The article provides a revenue breakdown for REGENXBIO Inc. (NASDAQ: RGNX), highlighting that the company generated $170.44 million USD last year. Its top-performing segment was Gene Therapies, contributing the entire $170.44 million, an increase from $83.33 million the previous year. Japan was the largest …

ARGX|argenx SE|Price:925.050|Chg%:+73.330

argenx SE (ARGX) is a biopharmaceutical company focused on developing antibody therapeutics for severe autoimmune diseases. Its fundamentals are stable with good growth potential, though its valuation is considered fairly valued. Analysts have rated ARGX as "Buy" with a target price of $1057.22, indicating …

argenex (NASDAQ:ARGX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Oppenheimer Issues Positive Forecast for argenex (NASDAQ:ARGX) Stock Price

Argenx (ENXTBR:ARGX) Stock Faces Margin Compression As 32.3% Profitability Tests Bullish Narrative

Guggenheim Issues Positive Forecast for argenex (NASDAQ:ARGX) Stock Price

argenx SE (ARGX) Stock Price, News, Quote & History

This article provides comprehensive financial data for argenx SE (ARGX), a commercial-stage biopharma company, including its stock price, historical performance, key financial metrics, and analyst ratings. It highlights the company's focus on developing therapies for autoimmune diseases and lists its main products and pipeline …

argenx SE (ARGNF) Q2 2026 Earnings Call Highlights: Robust Growth and Strategic Advances

This article first appeared on GuruFocus. Product Net Sales: $1.5 billion for Q2 2026, 60% year-over-year growth, 17% quarter-over-quarter growth. US Product Net Sales: $1.3 billion, 15% quarter-over-quarter growth. Japan Product Net Sales: $102 million, 55% quarter-over-quarter growth, including a $25 million one-off benefit. …

REGENXBIO Inc. (RGNX) stock price, news, quote and history

This article provides comprehensive financial data for REGENXBIO Inc. (RGNX), including its stock price, historical performance, earnings, and analyst insights. As of July 24, 2026, RGNX closed at $9.73, down 5.07%, with an after-hours price of $9.79. The company, a clinical-stage biotechnology firm, specializes …

Argenx stock steadies as investors weigh Vyvgart growth and profitability path

Argenx stock reflects a balance between strong Vyvgart revenue growth and ongoing operating losses. The company reported a significant increase in Vyvgart sales, reaching approximately $400 million in the latest quarter, while still incurring a net loss due to heavy investment in R&D and …

argenx (NASDAQ: ARGX) grows Q2 sales to $1.5B, profit $838M

argenx SE reported strong half-year 2026 results, driven by VYVGART sales, with product net sales reaching $1.5 billion in Q2 and $2.8 billion for the first six months. The company's profit doubled to $838 million for the half-year, and it ended the period with …

Euronext announces the cancellation of repurchased shares

Euronext Paris SA Euronext announces the cancellation of repurchased shares Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 23 July 2026 – Euronext today announced the cancellation of 1,967,993 ordinary shares following completion of its €250 million share repurchase programme on 27 …

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

argenx SE reported strong second-quarter 2026 financial results with $1.5 billion in global product net sales, a 60% year-over-year increase, driven by the expanded label launch of VYVGART and VYVGART Hytrulo for all gMG serotypes. The company is on track for several key registrational …

argenx VYVGART Sales Rise 60% as Pipeline Readouts Approach

argenex (NASDAQ:ARGX) Trading Up 6.3% on Strong Earnings

argenx SE GAAP EPS of $7.32 beats by $1.12, revenue of $1.52B beats by $90M

* argenx SE press release [https://seekingalpha.com/pr/20592469-argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q2 GAAP EPS of $7.32 beats by $1.12. * Revenue of $1.52B (+60.0% Y/Y) beats by $90M. * Cash flow from operating activities for the six months ended June 30, 2026 was $0.7 billion compared to …

Argenx Se (ARGX) Receives a Buy from Guggenheim

Guggenheim reiterated a Buy rating for Argenx Se (ARGX) with a price target of $1,135.00, according to an analyst report. This recommendation is supported by analyst Yatin Suneja's strong track record and a general "Strong Buy" consensus for ARGX with an average price target …

Argenx stock holds steady after 2025 revenue growth

Argenx stock has shown stability following strong revenue growth in 2025, with total revenue reaching EUR 2.13 billion, a 93% increase from 2024. The company also turned profitable, reporting diluted earnings per share of EUR 1.74 compared to a loss in the previous year, …